MaxCyte, Inc. (NASDAQ:MXCT) CEO Maher Masoud Purchases 75,000 Shares of Stock

MaxCyte, Inc. (NASDAQ:MXCT) CEO Maher Masoud purchased 75,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were acquired at an average cost of $1.37 per share, with a total value of $102,750.00. Following the completion of the transaction, the chief executive officer owned 175,000 shares in the company, valued at $239,750. This trade represents a 75.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

MaxCyte Price Performance

MXCT stock opened at $1.38 on Thursday. The company has a market capitalization of $147.12 million, a PE ratio of -3.21 and a beta of 1.23. MaxCyte, Inc. has a 12 month low of $1.26 and a 12 month high of $5.20. The firm’s 50-day moving average is $2.10 and its 200 day moving average is $2.75.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $9.57 million. Sell-side analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of MaxCyte by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company’s stock valued at $249,000 after buying an additional 2,584 shares in the last quarter. Invesco Ltd. boosted its stake in MaxCyte by 8.5% in the 4th quarter. Invesco Ltd. now owns 49,096 shares of the company’s stock worth $204,000 after purchasing an additional 3,848 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in MaxCyte by 123.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock worth $31,000 after purchasing an additional 4,173 shares in the last quarter. Moors & Cabot Inc. boosted its stake in MaxCyte by 34.4% in the 1st quarter. Moors & Cabot Inc. now owns 17,708 shares of the company’s stock worth $48,000 after purchasing an additional 4,528 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in MaxCyte by 9.8% in the 1st quarter. Hsbc Holdings PLC now owns 53,556 shares of the company’s stock worth $144,000 after purchasing an additional 4,765 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on MXCT shares. BTIG Research reaffirmed a “neutral” rating on shares of MaxCyte in a report on Monday. Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Stephens initiated coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price target for the company. Finally, William Blair lowered shares of MaxCyte from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.00.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.